Australia's most trusted
source of pharma news
Monday, 20 April 2026
Posted 20 April 2026 PM
Biointelect and 5 Horizons Ventures have joined forces to advance high-potential biotech and medtech companies through the critical stage of clinical development.
The strategic and investment alliance brings together venture-capital-as-a-service firm 5 Horizons Ventures’ investment model and global network with Biointelect’s deep capabilities in clinical development strategy, regulatory and pricing access, and evidence generation.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.